The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) has dropped by -9.83 compared to previous close of 4.78. Despite this, the company has seen a fall of -8.49% in its stock price over the last five trading days. accesswire.com reported 2024-12-12 that SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No.
Is It Worth Investing in Aptevo Therapeutics Inc (NASDAQ: APVO) Right Now?
APVO has 36-month beta value of 5.08. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APVO is 1.46M, and currently, short sellers hold a 16.55% ratio of that float. The average trading volume of APVO on January 01, 2025 was 326.91K shares.
APVO’s Market Performance
APVO’s stock has seen a -8.49% decrease for the week, with a -58.41% drop in the past month and a -30.70% fall in the past quarter. The volatility ratio for the week is 9.60%, and the volatility levels for the past 30 days are at 24.28% for Aptevo Therapeutics Inc The simple moving average for the past 20 days is -31.54% for APVO’s stock, with a -84.21% simple moving average for the past 200 days.
Analysts’ Opinion of APVO
Piper Jaffray, on the other hand, stated in their research note that they expect to see APVO reach a price target of $6. The rating they have provided for APVO stocks is “Overweight” according to the report published on October 05th, 2017.
APVO Trading at -49.75% from the 50-Day Moving Average
After a stumble in the market that brought APVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.92% of loss for the given period.
Volatility was left at 24.28%, however, over the last 30 days, the volatility rate increased by 9.60%, as shares sank -50.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.32% lower at present.
During the last 5 trading sessions, APVO fell by -8.49%, which changed the moving average for the period of 200-days by -97.85% in comparison to the 20-day moving average, which settled at $6.30. In addition, Aptevo Therapeutics Inc saw -98.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APVO
Current profitability levels for the company are sitting at:
- -27.28 for the present operating margin
- 0.65 for the gross margin
The net margin for Aptevo Therapeutics Inc stands at -26.3. The total capital return value is set at -2.66. Equity return is now at value -250.96, with -113.61 for asset returns.
Currently, EBITDA for the company is -28.31 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 3.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.70.
Conclusion
To put it simply, Aptevo Therapeutics Inc (APVO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
